These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 17044318

  • 1. Using the new HPV vaccines in clinical practice.
    Widdice LE, Kahn JA.
    Cleve Clin J Med; 2006 Oct; 73(10):929-35. PubMed ID: 17044318
    [Abstract] [Full Text] [Related]

  • 2. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE, Vuocolo S.
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [Abstract] [Full Text] [Related]

  • 3. Currently approved prophylactic HPV vaccines.
    Harper DM.
    Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
    [Abstract] [Full Text] [Related]

  • 4. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 5. [Diseases caused by human papilloma viruses].
    Zollner U, Schwarz TF.
    Dtsch Med Wochenschr; 2011 May 01; 136(20):1067-72. PubMed ID: 21560109
    [Abstract] [Full Text] [Related]

  • 6. A human papillomavirus vaccine.
    Med Lett Drugs Ther; 2011 May 01; 48(1241-1242):65-6. PubMed ID: 16977280
    [Abstract] [Full Text] [Related]

  • 7. Human papillomavirus vaccines and vaccine implementation.
    de Sanjosé S, Alemany L, Castellsagué X, Bosch FX.
    Womens Health (Lond); 2008 Nov 01; 4(6):595-604. PubMed ID: 19072462
    [Abstract] [Full Text] [Related]

  • 8. Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines?
    Stanley M.
    J Infect; 2016 Jul 05; 72 Suppl():S23-8. PubMed ID: 27211079
    [Abstract] [Full Text] [Related]

  • 9. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT, Castellsagué X, Garland SM.
    Vaccine; 2012 Nov 20; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [Abstract] [Full Text] [Related]

  • 10. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
    Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C.
    Clin Infect Dis; 2016 Aug 15; 63(4):519-27. PubMed ID: 27230391
    [Abstract] [Full Text] [Related]

  • 11. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
    Luxembourg A, Moeller E.
    Expert Rev Vaccines; 2017 Nov 15; 16(11):1119-1139. PubMed ID: 28956458
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic vaccines for human papillomavirus: a bright future for cervical cancer prevention.
    Szarewski A.
    J Med Screen; 2005 Nov 15; 12(4):163-5. PubMed ID: 16417690
    [No Abstract] [Full Text] [Related]

  • 13. HPV vaccination and cervical cancer.
    Szarewski A.
    Curr Oncol Rep; 2012 Dec 15; 14(6):559-67. PubMed ID: 22890794
    [Abstract] [Full Text] [Related]

  • 14. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL, Joura EA.
    Drugs; 2010 Dec 24; 70(18):2449-74. PubMed ID: 21142263
    [Abstract] [Full Text] [Related]

  • 15. Start early to prevent genital HPV infection-and cervical cancer.
    Heavey E.
    Nursing; 2008 May 24; 38(5):62-3. PubMed ID: 18431214
    [No Abstract] [Full Text] [Related]

  • 16. [Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project].
    Sturegård E, Johnsson A, Gustafsson E, Dillner J.
    Lakartidningen; 2008 May 24; 105(50):3648-50. PubMed ID: 19177930
    [No Abstract] [Full Text] [Related]

  • 17. Epidemiology and prevention of Human Papillomavirus.
    Manini I, Montomoli E.
    Ann Ig; 2018 May 24; 30(4 Supple 1):28-32. PubMed ID: 30062377
    [Abstract] [Full Text] [Related]

  • 18. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL.
    Drugs; 2014 Jul 24; 74(11):1253-83. PubMed ID: 25022951
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E, López-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J.
    Vaccine; 2017 Jun 05; 35(25):3342-3346. PubMed ID: 28499554
    [Abstract] [Full Text] [Related]

  • 20. Population impact of HPV vaccines: summary of early evidence.
    Hariri S, Markowitz LE, Dunne EF, Unger ER.
    J Adolesc Health; 2013 Dec 05; 53(6):679-82. PubMed ID: 24263069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.